查看购物车
  • Traditional Chinese
  • English
  • Japanese
体外诊断试剂的全球市场：按类型、技术、应用、测试类型、最终用户、地区划分 - 预测至 2029 年
市场调查报告书
商品编码
1613791

体外诊断试剂的全球市场：按类型、技术、应用、测试类型、最终用户、地区划分 - 预测至 2029 年

IVD Reagents Market by Type, technology, Application, Test Type, End User & Region - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 424 Pages | 订单完成后即时交付

价格

预计2024年全球体外诊断试剂市场规模为604.5亿美元，预测期内复合年增长率为7.7%，预计2029年将达到874.1亿美元。

体外诊断 (IVD) 技术的日益普及增加了对 IVD 试剂的需求。因此，随着新的诊断技术获得 FDA 和 EMA 等监管机构的批准，对 IVD 试剂的需求预计将增加。

调查范围
调查年份 2022-2029
基准年 2023年
预测期 2024-2029
考虑单位 金额（百万美元）
按细分市场 按类型、技术、应用程式、测试类型、最终用户、地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东/非洲、海湾合作委员会国家

按类型划分，IVD 试剂市场分为抗体、抗原、精製蛋白、胜肽、寡核苷酸、核酸探针和其他 IVD 试剂。基于 PCR 的诊断测试的激增正在推动 IVD 试剂市场对寡核苷酸的需求。寡核苷酸广泛应用于感染疾病和基因检测。

依应用划分，体外诊断试剂市场分为感染疾病、肿瘤学、内分泌学、心臟病学、血液筛检、基因检测、自体免疫疾病、过敏诊断、药物监测和检测等应用。由于感染疾病研发活动和产品核可数量不断增加，感染疾病领域在体外诊断试剂市场中占有最高份额。

全球IVD试剂市场分为六个地区：北美、欧洲、亚太地区、中东和非洲、拉丁美洲和海湾合作委员会国家。在预测期内，IVD试剂市场预计将在亚太地区成长最快。在预测期内，由于医疗保健支出增加和广泛的人口基础等因素，亚太市场预计将以最高的速度发展。

该报告研究了全球体外诊断试剂市场，包括按类型、技术、应用、测试类型、最终用户、地区和参与市场的公司概况分類的趋势。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 介绍
  • 市场动态
  • 影响客户业务的趋势/干扰
  • 价格分析
  • 价值链分析
  • 供应链分析
  • 生态系分析
  • 投资金筹措场景
  • 技术分析
  • 专利分析
  • 贸易分析
  • 2024-2025年重大会议和活动
  • 波特五力分析
  • 监管分析
  • 主要相关人员和采购标准
  • 人工智慧/产生人工智慧对 IVD 试剂市场的影响

第六章 IVD 试剂市场（按类型）

  • 介绍
  • 抗体
  • 抗原、精製蛋白、胜肽
  • 寡核苷酸
  • 核酸探针
  • 其他的

第七章 IVD试剂市场（依技术分）

  • 介绍
  • 免疫测定法
  • 临床化学
  • 分子诊断
  • 血液学
  • 微生物学
  • 凝血和止血
  • 尿液检查
  • 层析法和质谱分析
  • 免疫组织化学

第八章 IVD试剂市场（依用途）

  • 介绍
  • 感染疾病
  • 肿瘤学
  • 内分泌学
  • 心臟病
  • 验血
  • 基因检测
  • 自体免疫疾病
  • 过敏诊断
  • 药物监测和检测
  • 其他的

第九章 IVD试剂市场（依测试类型）

  • 介绍
  • 临床检查
  • 照护现场测试

第10章 IVD试剂市场（依最终用户）

  • 介绍
  • 医院和诊所
  • 临床实验室
  • 血库
  • 居家照护
  • 製药和生物技术公司
  • 学术机构
  • 其他的

第十一章 IVD试剂市场（分地区）

  • 介绍
  • 北美洲
    • 北美宏观经济前景
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 亚太宏观经济展望
    • 日本
    • 中国
    • 印度
    • 其他的
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他的
  • 中东/非洲
    • 免疫学、产前检测和癌症检测日益受到关注并推动市场发展
    • 中东和非洲宏观经济前景
  • 海湾合作委员会国家
    • 海湾合作委员会国家的宏观经济前景
    • 沙乌地阿拉伯王国
    • 阿拉伯聯合大公国
    • 其他的

第十二章竞争格局

  • 概述
  • 主要参与企业的策略/优势，2023 年
  • 2021-2023 年收益分析
  • 2023 年市场占有率分析
  • 企业价值评估及财务指标
  • 品牌/产品比较
  • 企业评估矩阵：主要参与企业，2023
  • 企业评估矩阵：Start-Ups/小型企业，2023 年
  • 竞争场景

第十三章 公司简介

  • 主要参与企业
    • DANAHER CORPORATION
    • F. HOFFMANN-LA ROCHE LTD.
    • ABBOTT
    • SIEMENS HEALTHINEERS AG
    • THERMO FISHER SCIENTIFIC INC.
    • ILLUMINA, INC.
    • BIOMERIEUX
    • BD
    • HOLOGIC, INC.
    • BIO-RAD LABORATORIES, INC.
    • SYSMEX CORPORATION
    • QIAGEN NV
    • AGILENT TECHNOLOGIES, INC.
    • REVVITY
    • DIASORIN SPA
    • GRIFOLS, SA
    • WERFEN, SA
    • QUIDELORTHO CORPORATION
    • CHEMBIO DIAGNOSTICS, INC.
    • SURMODICS, INC.
    • MERCK KGAA
  • 其他公司
    • MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
    • CANVAX
    • PRESTIGE DIAGNOSTICS
    • ADALTIS SRL
    • RANDOX LABORATORIES LTD.

第十四章附录

Product Code: MD 9227

The global IVD reagents market is valued at an estimated 87.41 billion in 2029 and is projected to reach USD 60.45 billion by 2024, at a CAGR of 7.7% during the forecast period. The increasing adoption of IVD technologies has led to a growing need of IVD reagents. The demand for IVD reagents is therefore expected to increase as new diagnostic technologies are getting FDA, EMA approvals from regulatory bodies.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD Million)
SegmentsBy Type, technology, application, test type, and end user.
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries

"The oligonucleotide segment is projected to witness the highest growth rate in the IVD reagents market, by type, during the forecast period."

Based on type, the IVD reagents market is segmented into antibodies, antigen, purified proteins, and peptides, oligonucleotides, nucleic acid probes, and other IVD reagents. The growing adoption of PCR-based tests in diagnostics has boosted the demand for oligonucleotide in the IVD reagents market. Oligonucleotides have wide range of applications in infectious diseases and genetic testing.

"The infectious disease segment to witness the highest share in the IVD reagents market, in 2023, by application"

Based on application, the IVD reagents market is segmented into infectious diseases, oncological applications, endocrinological applications, cardiological applications, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing and other applications. The infectious diseases segment experience highest market share of IVD reagents market due to rising number of R&D activities and product approvals for infectious disease applications.

"The Asia Pacific region is projected to witness highest growth rate in the IVD reagents market during the forecast period"

The global IVD reagents market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. Over the span of the forecast period, the IVD reagents market is expected to grow at the fastest rate in the Asia Pacific region. Over the projected period, the Asia Pacific market is expected to develop at the greatest rate due to factors such increasing healthcare spending and an extensive population base.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 42%, Tier 2 - 30%, and Tier 3 - 28%
  • By Designation: C-level - 46%, Director-level - 23%, and Others - 31%
  • By Region: North America - 23%, Europe - 44%, Asia Pacific - 28%, Latin America - 3%, Middle East & Africa - 1%, and the GCC Countries - 1%

Lists of Companies Profiled in the Report:

Danaher Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), BioMerieux (France), BD (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), DiaSorin S.p.A (Italy), Grifols, S.A. (Spain), Werfen, S.A. (Spain), QuidelOrtho Corporation (US), Chembio Diagnostics, Inc. (US), Surmodics, Inc. (US), Merck KGaA (Germany), MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Tokyo), Canvax (Spain), Prestige Diagnostics (US), Adaltis S.r.l. (Italy), and Randox Laboratories Ltd. (UK)

Study Coverage:

In this report, the IVD reagents market has been categorized based on type (antibodies, antigen, purified proteins, and peptides, oligonucleotides, nucleic acid probes, and other IVD reagents), technology (immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, chromatography & mass spectrometry, immunohistochemistry), application (infectious diseases, oncological applications, endocrinological application, cardiology application, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing, and other applications), test type (laboratory test, and point-of-care tests), end user (hospitals & clinics, clinical laboratories, blood banks, home care settings, pharmaceutical & biotechnology companies, academic institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC Countries).

Information regarding the main drivers, restraints, opportunities, and challenges influencing the IVD reagents market's expansion is includes detail in this study. An intensive study of the key players in the IVD reagents market has been done to provide insights into their business profile, service offered, note worthy strategies, acquisitions and expansions, and other deals made pertaining to the market. This study examines the fragmented landscape of emerging IVD reagents startups.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall IVD reagents marketand the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, opportunities, and restaints.

The report provides insights on the following pointers:

  • Analysis of key drivers: (growing geriatric population, gradual shift towards point-of-care testing and automated analyzers, rise in early diagnosis and personalized medicine, increasing adoption of third-party quality controls, growing biotechnology and biopharmaceutical industries, increasing funding for R&D activities), restraints (unfavorable reimbursement scenario, stringent regulatory requirements), opportunities (increasing development of biomarkers, rising significance of companion diagnostics, market growth opportunities in emerging economies, and growing trend of digitalization), and challenges (operational challenges in clinical process) influencing the growth of the in IVD reagents market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the IVD reagents market across varied regions.
  • Market Diversification: Exhaustive information about untapped geographies, and investments in the IVD reagents market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like include F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), and Thermo Fisher Scientific Inc. (US) are among others, in the IVD reagents market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 MARKET RECONCILIATION

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key industry insights
      • 2.1.2.3 Key data from primary sources
      • 2.1.2.4 Breakdown of primary interviews
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
      • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.2.1.3 Approach 3: Primary interviews
      • 2.2.1.4 Growth forecast
      • 2.2.1.5 CAGR projections
    • 2.2.2 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 RESEARCH ASSUMPTIONS
    • 2.4.1 STUDY-RELATED ASSUMPTIONS
    • 2.4.2 PARAMETRIC ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS
  • 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 IVD REAGENTS MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: IVD REAGENTS MARKET, BY COUNTRY
  • 4.3 NORTH AMERICA: IVD REAGENTS MARKET, BY TEST TYPE AND COUNTRY
  • 4.4 IVD REAGENTS MARKET, BY COUNTRY

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing geriatric population
      • 5.2.1.2 Gradual shift toward point-of-care testing and automated analyzers
      • 5.2.1.3 Rise in early diagnosis and personalized medicine
      • 5.2.1.4 Increasing adoption of third-party quality controls
      • 5.2.1.5 Growing biotechnology and biopharmaceutical industries
      • 5.2.1.6 Increasing funding for R&D activities
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement scenario
      • 5.2.2.2 Stringent regulatory requirements
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing development of biomarkers
      • 5.2.3.2 Rising significance of companion diagnostics
      • 5.2.3.3 Market growth opportunities in emerging economies
      • 5.2.3.4 Growing trend of digitalization
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Operational challenges in clinical process
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION
    • 5.4.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION
    • 5.4.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    • 5.9.1 KEY TECHNOLOGIES
    • 5.9.2 ADJACENT TECHNOLOGIES
      • 5.9.2.1 Multiplexed point-of-care testing
      • 5.9.2.2 Nucleic acid lateral flow immunoassay
      • 5.9.2.3 DNA-based detection
      • 5.9.2.4 Immunodiagnostics
      • 5.9.2.5 Dual path technology
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE ANALYSIS
    • 5.11.1 IMPORT DATA
    • 5.11.2 EXPORT DATA
  • 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
  • 5.13 PORTER'S FIVE FORCES ANALYSIS
    • 5.13.1 THREAT OF NEW ENTRANTS
    • 5.13.2 THREAT OF SUBSTITUTES
    • 5.13.3 BARGAINING POWER OF SUPPLIERS
    • 5.13.4 BARGAINING POWER OF BUYERS
    • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 REGULATORY ANALYSIS
    • 5.14.1 REGULATORY LANDSCAPE
      • 5.14.1.1 North America
        • 5.14.1.1.1 US
        • 5.14.1.1.2 Canada
      • 5.14.1.2 Europe
      • 5.14.1.3 Asia Pacific
        • 5.14.1.3.1 China
        • 5.14.1.3.2 Japan
        • 5.14.1.3.3 India
      • 5.14.1.4 Latin America
        • 5.14.1.4.1 Brazil
      • 5.14.1.5 Middle East
    • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
      • 5.14.2.1 North America
      • 5.14.2.2 Europe
      • 5.14.2.3 Asia Pacific
      • 5.14.2.4 Latin America
      • 5.14.2.5 Middle East & Africa
      • 5.14.2.6 GCC Countries
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.15.2 BUYING CRITERIA
  • 5.16 IMPACT OF AI/GENERATIVE AI ON IVD REAGENTS MARKET
    • 5.16.1 INTRODUCTION
    • 5.16.2 MARKET POTENTIAL FOR IVD REAGENTS
    • 5.16.3 AI USE CASES
    • 5.16.4 KEY COMPANIES IMPLEMENTING AI
    • 5.16.5 FUTURE OF GENERATIVE AI ON IVD REAGENTS

6 IVD REAGENTS MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 ANTIBODIES
    • 6.2.1 MONOCLONAL ANTIBODIES
      • 6.2.1.1 Increasing incidence of cancer to stimulate growth
    • 6.2.2 POLYCLONAL ANTIBODIES
      • 6.2.2.1 Rising prevalence of infectious diseases and autoimmune disorders to support growth
  • 6.3 ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES
    • 6.3.1 INCREASING FOCUS ON ADVANCED PRECISION MEDICINE TO ENCOURAGE GROWTH
  • 6.4 OLIGONUCLEOTIDES
    • 6.4.1 GROWING INCLINATION TOWARD MOLECULAR DIAGNOSTICS TO DRIVE MARKET
  • 6.5 NUCLEIC ACID PROBES
    • 6.5.1 NEED FOR EARLY DISEASE DETECTION AND MONITORING LOW-ABUNDANCE BIOMARKERS TO AID GROWTH
  • 6.6 OTHER IVD REAGENTS

7 IVD REAGENTS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 IMMUNOASSAYS
    • 7.2.1 RISING TREND OF AUTOMATION TO PROMOTE GROWTH
  • 7.3 CLINICAL CHEMISTRY
    • 7.3.1 RISING PREVALENCE OF DIABETES TO BOOST SEGMENT
  • 7.4 MOLECULAR DIAGNOSTICS
    • 7.4.1 GROWING DEMAND FOR BLOOD SCREENING AND POINT-OF-CARE TESTING TO FUEL MARKET
  • 7.5 HEMATOLOGY
    • 7.5.1 INCREASING FOCUS ON STEM CELL RESEARCH TO SPEED UP GROWTH
  • 7.6 MICROBIOLOGY
    • 7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET
  • 7.7 COAGULATION & HEMOSTASIS
    • 7.7.1 GROWING USE OF ANTICOAGULATION THERAPY TO PROPEL MARKET
  • 7.8 URINALYSIS
    • 7.8.1 RISING PREVALENCE OF KIDNEY DISEASES TO SUPPORT MARKET GROWTH
  • 7.9 CHROMATOGRAPHY & MASS SPECTROMETRY
    • 7.9.1 INCREASING APPLICATIONS IN DISEASE SCREENING, FORENSIC ANALYSIS, AND DRUG THERAPY TO BOOST MARKET
  • 7.10 IMMUNOHISTOCHEMISTRY
    • 7.10.1 GROWING NUMBER OF LABORATORY TESTS FOR CANCER DIAGNOSIS TO DRIVE MARKET

8 IVD REAGENTS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 INFECTIOUS DISEASES
    • 8.2.1 INCREASING PRODUCT LAUNCHES AND APPROVALS TO BOOST MARKET
  • 8.3 ONCOLOGICAL APPLICATIONS
    • 8.3.1 GROWING EMPHASIS ON EARLY DIAGNOSIS AND QUALITY TREATMENT TO FUEL MARKET
  • 8.4 ENDOCRINOLOGICAL APPLICATIONS
    • 8.4.1 RISING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO SUSTAIN GROWTH
  • 8.5 CARDIOLOGICAL APPLICATIONS
    • 8.5.1 CHANGING LIFESTYLES IN DEVELOPED AND DEVELOPING COUNTRIES TO PROPEL MARKET
  • 8.6 BLOOD SCREENING
    • 8.6.1 RISING ADOPTION OF AUTOMATED DIAGNOSTIC INSTRUMENTS TO FACILITATE GROWTH
  • 8.7 GENETIC TESTING
    • 8.7.1 INCREASING ADOPTION OF GENETIC TESTING TO DIAGNOSE RARE AND FATAL DISEASES TO SUSTAIN GROWTH
  • 8.8 AUTOIMMUNE DISEASES
    • 8.8.1 GROWING ADVANCEMENTS IN LABORATORY TECHNOLOGY, REAGENTS, AND ALTERNATIVE ASSAY METHODOLOGIES TO DRIVE MARKET
  • 8.9 ALLERGY DIAGNOSTICS
    • 8.9.1 GROWING FOCUS ON ALLERGY THERAPY AND PREVENTION TO ACCELERATE GROWTH
  • 8.10 DRUG MONITORING & TESTING
    • 8.10.1 GROWING IMPLEMENTATION OF DRUGS-OF-ABUSE TESTING TO DRIVE MARKET
  • 8.11 OTHER APPLICATIONS

9 IVD REAGENTS MARKET, BY TEST TYPE

  • 9.1 INTRODUCTION
  • 9.2 LABORATORY TESTS
    • 9.2.1 INCREASING NEED FOR AUTOMATION TO EXPEDITE GROWTH
  • 9.3 POINT-OF-CARE TESTS
    • 9.3.1 NEED TO CLOSELY MONITOR PATIENT CONDITIONS TO AUGMENT GROWTH

10 IVD REAGENTS MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS & CLINICS
    • 10.2.1 INCREASING SPECIALTY DIAGNOSTIC TESTS TO ACCELERATE GROWTH
  • 10.3 CLINICAL LABORATORIES
    • 10.3.1 LARGE REFERENCE LABORATORIES
      • 10.3.1.1 Need for specialized testing capabilities and minimal turnaround time to boost market
    • 10.3.2 SMALL & MEDIUM-SIZED LABORATORIES
      • 10.3.2.1 Growing adoption of automated and semi-automated instruments to support growth
  • 10.4 BLOOD BANKS
    • 10.4.1 GROWING NUMBER OF TRAUMA CASES AND AVAILABILITY OF SOPHISTICATED SURGICAL PROCEDURES TO FUEL MARKET
  • 10.5 HOME CARE SETTINGS
    • 10.5.1 GROWING PREFERENCE FOR AT-HOME TESTING KITS TO DRIVE MARKET
  • 10.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.6.1 INCREASING RESEARCH & DEVELOPMENT EFFORTS TO CONTRIBUTE TO GROWTH
  • 10.7 ACADEMIC INSTITUTES
    • 10.7.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS TO FAVOR GROWTH
  • 10.8 OTHER END USERS

11 IVD REAGENTS MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 Established reimbursement framework to drive market
    • 11.2.3 CANADA
      • 11.2.3.1 Rising incidence of chronic and infectious lifestyle diseases to propel market
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 Increasing investments in clinical diagnostics research to drive market
    • 11.3.3 UK
      • 11.3.3.1 Rising adoption of genome-based testing to promote growth
    • 11.3.4 FRANCE
      • 11.3.4.1 High healthcare expenditure and rising investments in genomic medicine to boost market
    • 11.3.5 ITALY
      • 11.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to support market growth
    • 11.3.6 SPAIN
      • 11.3.6.1 Rising adoption of immunoassay reagents to drive market
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 JAPAN
      • 11.4.2.1 Rise in social health insurance programs to encourage growth
    • 11.4.3 CHINA
      • 11.4.3.1 Growing focus on preventive care to boost demand
    • 11.4.4 INDIA
      • 11.4.4.1 Rising prevalence of chronic diseases to fuel market
    • 11.4.5 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Rising prevalence of diabetes to stimulate growth
    • 11.5.3 MEXICO
      • 11.5.3.1 Growing establishment of clinical laboratories to boost market
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 GROWING FOCUS ON IMMUNOLOGY AND PRENATAL & CANCER TESTING TO DRIVE MARKET
    • 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.7 GCC COUNTRIES
    • 11.7.1 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
    • 11.7.2 KINGDOM OF SAUDI ARABIA
      • 11.7.2.1 Rising healthcare expenditure to promote growth
    • 11.7.3 UNITED ARAB EMIRATES
      • 11.7.3.1 Increasing development of advanced healthcare infrastructure to expedite growth
    • 11.7.4 OTHER GCC COUNTRIES

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IVD REAGENTS MARKET, 2021-2023
  • 12.3 REVENUE ANALYSIS, 2021-2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.6 BRAND/PRODUCT COMPARISON
  • 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 12.7.1 STARS
    • 12.7.2 EMERGING LEADERS
    • 12.7.3 PERVASIVE PLAYERS
    • 12.7.4 PARTICIPANTS
    • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 12.7.5.1 Company footprint
      • 12.7.5.2 Technology footprint
      • 12.7.5.3 Application footprint
      • 12.7.5.4 Test type footprint
      • 12.7.5.5 Region footprint
  • 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 12.8.1 PROGRESSIVE COMPANIES
    • 12.8.2 RESPONSIVE COMPANIES
    • 12.8.3 DYNAMIC COMPANIES
    • 12.8.4 STARTING BLOCKS
    • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
      • 12.8.5.1 Detailed list of key startups/SMEs
      • 12.8.5.2 Competitive benchmarking of key startups/SMEs
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES AND APPROVALS
    • 12.9.2 DEALS
    • 12.9.3 EXPANSIONS
    • 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 DANAHER CORPORATION
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Deals
        • 13.1.1.3.2 Expansions
        • 13.1.1.3.3 Other developments
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Right to win
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses and competitive threats
    • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Deals
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Right to win
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses and competitive threats
    • 13.1.3 ABBOTT
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Deals
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Right to win
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses and competitive threats
    • 13.1.4 SIEMENS HEALTHINEERS AG
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Deals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Right to win
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses and competitive threats
    • 13.1.5 THERMO FISHER SCIENTIFIC INC.
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Deals
        • 13.1.5.3.2 Expansions
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Right to win
        • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.3 Weaknesses and competitive threats
    • 13.1.6 ILLUMINA, INC.
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Deals
    • 13.1.7 BIOMERIEUX
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Deals
    • 13.1.8 BD
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Deals
    • 13.1.9 HOLOGIC, INC.
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Product launches and approvals
        • 13.1.9.3.2 Deals
    • 13.1.10 BIO-RAD LABORATORIES, INC.
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
      • 13.1.10.3 Recent developments
        • 13.1.10.3.1 Deals
    • 13.1.11 SYSMEX CORPORATION
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Product launches and approvals
        • 13.1.11.3.2 Deals
        • 13.1.11.3.3 Expansions
    • 13.1.12 QIAGEN N.V.
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products offered
      • 13.1.12.3 Recent developments
        • 13.1.12.3.1 Deals
    • 13.1.13 AGILENT TECHNOLOGIES, INC.
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products offered
      • 13.1.13.3 Recent developments
        • 13.1.13.3.1 Deals
        • 13.1.13.3.2 Expansions
    • 13.1.14 REVVITY
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products offered
      • 13.1.14.3 Recent developments
        • 13.1.14.3.1 Deals
        • 13.1.14.3.2 Other developments
    • 13.1.15 DIASORIN S.P.A.
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products offered
      • 13.1.15.3 Recent developments
        • 13.1.15.3.1 Deals
    • 13.1.16 GRIFOLS, S.A.
      • 13.1.16.1 Business overview
      • 13.1.16.2 Products offered
      • 13.1.16.3 Recent developments
        • 13.1.16.3.1 Deals
    • 13.1.17 WERFEN, S.A.
      • 13.1.17.1 Business overview
      • 13.1.17.2 Products offered
      • 13.1.17.3 Recent developments
        • 13.1.17.3.1 Deals
    • 13.1.18 QUIDELORTHO CORPORATION
      • 13.1.18.1 Business overview
      • 13.1.18.2 Products offered
      • 13.1.18.3 Recent developments
        • 13.1.18.3.1 Deals
        • 13.1.18.3.2 Expansions
    • 13.1.19 CHEMBIO DIAGNOSTICS, INC.
      • 13.1.19.1 Business overview
      • 13.1.19.2 Products offered
    • 13.1.20 SURMODICS, INC.
      • 13.1.20.1 Business overview
      • 13.1.20.2 Products offered
    • 13.1.21 MERCK KGAA
      • 13.1.21.1 Business overview
      • 13.1.21.2 Products offered
  • 13.2 OTHER PLAYERS
    • 13.2.1 MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
    • 13.2.2 CANVAX
    • 13.2.3 PRESTIGE DIAGNOSTICS
    • 13.2.4 ADALTIS S.R.L.
    • 13.2.5 RANDOX LABORATORIES LTD.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 IVD REAGENTS MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IVD REAGENTS MARKET: RISK ASSESSMENT
  • TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION, 2022 VS. 2030 VS. 2050
  • TABLE 4 RECENT DEVELOPMENTS IN IVD REAGENTS MARKET IN EMERGING ECONOMIES, 2022-2023
  • TABLE 5 AVERAGE SELLING PRICE TREND OF KEY PLAYERS FOR TOP 2 APPLICATIONS, 2021-2023 (USD)
  • TABLE 6 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION, 2021-2023 (USD)
  • TABLE 7 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2021-2023 (USD)
  • TABLE 8 IVD REAGENTS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 9 IVD REAGENTS MARKET: KEY TECHNOLOGIES
  • TABLE 10 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 11 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 12 IVD REAGENTS MARKET: KEY CONFERENCES AND EVENTS, 2024-2025
  • TABLE 13 IVD REAGENTS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 14 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL FOR IVD REAGENTS
  • TABLE 15 US: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
  • TABLE 16 CANADA: CLASSIFICATION OF IVD PRODUCTS
  • TABLE 17 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
  • TABLE 18 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES
  • TABLE 19 EUROPE: CLASSIFICATION OF IVD REAGENTS
  • TABLE 20 EUROPE: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
  • TABLE 21 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
  • TABLE 22 JAPAN: CLASSIFICATION OF IVD REAGENTS
  • TABLE 23 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
  • TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 29 GCC COUNTRIES: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD REAGENTS, BY END USER (%)
  • TABLE 31 KEY BUYING CRITERIA FOR IVD REAGENTS, BY END USER
  • TABLE 32 IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 33 COMPANIES PROVIDING ANTIBODIES
  • TABLE 34 ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 35 ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 36 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 LATIN AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 GCC COUNTRIES: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 41 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 42 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 47 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 48 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 COMPANIES PROVIDING ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES
  • TABLE 54 ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 55 NORTH AMERICA: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 56 EUROPE: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 LATIN AMERICA: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 GCC COUNTRIES: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 COMPANIES PROVIDING OLIGONUCLEOTIDES
  • TABLE 61 OLIGONUCLEOTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 EUROPE: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 GCC COUNTRIES: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 COMPANIES PROVIDING NUCLEIC ACID PROBES
  • TABLE 68 NUCLEIC ACID PROBES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 69 NORTH AMERICA: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 70 EUROPE: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 LATIN AMERICA: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 73 GCC COUNTRIES: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 COMPANIES PROVIDING OTHER IVD REAGENTS
  • TABLE 75 OTHER IVD REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 76 NORTH AMERICA: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 77 EUROPE: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 78 ASIA PACIFIC: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 79 LATIN AMERICA: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 80 GCC COUNTRIES: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 81 IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 82 IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 83 NORTH AMERICA: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 84 EUROPE: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 85 ASIA PACIFIC: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 86 LATIN AMERICA: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 GCC COUNTRIES: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 90 EUROPE: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 92 LATIN AMERICA: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 93 GCC COUNTRIES: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 94 IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 95 NORTH AMERICA: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 96 EUROPE: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 97 ASIA PACIFIC: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 98 LATIN AMERICA: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 99 GCC COUNTRIES: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 100 IVD REAGENTS MARKET FOR HEMATOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 101 NORTH AMERICA: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 102 EUROPE: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 104 LATIN AMERICA: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 105 GCC COUNTRIES: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 106 IVD REAGENTS MARKET FOR MICROBIOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 107 NORTH AMERICA: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 108 EUROPE: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 110 LATIN AMERICA: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 111 GCC COUNTRIES: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 112 IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 113 NORTH AMERICA: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 114 EUROPE: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 116 LATIN AMERICA: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 117 GCC COUNTRIES: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 118 IVD REAGENTS MARKET FOR URINALYSIS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 119 NORTH AMERICA: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 120 EUROPE: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 122 LATIN AMERICA: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 123 GCC COUNTRIES: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 124 IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 125 NORTH AMERICA: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 126 EUROPE: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 128 LATIN AMERICA: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 129 GCC COUNTRIES: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 130 IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 131 NORTH AMERICA: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 132 EUROPE: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 134 LATIN AMERICA: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 135 GCC COUNTRIES: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 136 IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 137 IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 138 NORTH AMERICA: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 139 EUROPE: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 140 ASIA PACIFIC: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 141 LATIN AMERICA: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 142 GCC COUNTRIES: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 143 ESTIMATED NUMBER OF NEW CASES OF CANCER FOR 0-85+ YEARS OF AGE, 2022 VS. 2030
  • TABLE 144 IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 145 NORTH AMERICA: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 146 EUROPE: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 147 ASIA PACIFIC: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 148 LATIN AMERICA: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 149 GCC COUNTRIES: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 150 IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 151 NORTH AMERICA: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 152 EUROPE: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 154 LATIN AMERICA: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 155 GCC COUNTRIES: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 156 IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 157 NORTH AMERICA: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 158 EUROPE: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 159 ASIA PACIFIC: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 160 LATIN AMERICA: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 161 GCC COUNTRIES: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 162 IVD REAGENTS MARKET FOR BLOOD SCREENING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 163 NORTH AMERICA: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 164 EUROPE: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 166 LATIN AMERICA: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 167 GCC COUNTRIES: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 168 IVD REAGENTS MARKET FOR GENETIC TESTING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 169 NORTH AMERICA: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 170 EUROPE: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 171 ASIA PACIFIC: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 172 LATIN AMERICA: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 173 GCC COUNTRIES: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 174 IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 175 NORTH AMERICA: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 176 EUROPE: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 178 LATIN AMERICA: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 179 GCC COUNTRIES: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 180 IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 181 NORTH AMERICA: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 182 EUROPE: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 184 LATIN AMERICA: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 185 GCC COUNTRIES: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 186 KEY PRODUCTS FOR DRUG MONITORING
  • TABLE 187 IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 188 NORTH AMERICA: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 189 EUROPE: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 190 ASIA PACIFIC: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 191 LATIN AMERICA: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 192 GCC COUNTRIES: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 193 IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 194 NORTH AMERICA: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 195 EUROPE: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 196 ASIA PACIFIC: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 197 LATIN AMERICA: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 198 GCC COUNTRIES: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 199 IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 200 IVD REAGENTS MARKET FOR LABORATORY TESTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 201 NORTH AMERICA: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 202 EUROPE: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 203 ASIA PACIFIC: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 204 LATIN AMERICA: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 205 GCC COUNTRIES: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 206 IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 207 NORTH AMERICA: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 208 EUROPE: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 209 ASIA PACIFIC: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 210 LATIN AMERICA: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 211 GCC COUNTRIES: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 212 IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 213 IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 214 NORTH AMERICA: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 215 EUROPE: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 217 LATIN AMERICA: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 218 GCC COUNTRIES: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 219 IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 220 IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 221 NORTH AMERICA: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 222 EUROPE: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 223 ASIA PACIFIC: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 224 LATIN AMERICA: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 225 GCC COUNTRIES: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 226 IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 227 NORTH AMERICA: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 228 EUROPE: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 230 LATIN AMERICA: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 231 GCC COUNTRIES: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 232 IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 233 NORTH AMERICA: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 234 EUROPE: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 235 ASIA PACIFIC: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 236 LATIN AMERICA: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 237 GCC COUNTRIES: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 238 IVD REAGENTS MARKET FOR BLOOD BANKS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 239 NORTH AMERICA: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 240 EUROPE: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 242 LATIN AMERICA: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 243 GCC COUNTRIES: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 244 IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 245 NORTH AMERICA: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 246 EUROPE: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 247 ASIA PACIFIC: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 248 LATIN AMERICA: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 249 GCC COUNTRIES: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 250 IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 251 NORTH AMERICA: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 252 EUROPE: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 253 ASIA PACIFIC: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 254 LATIN AMERICA: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 255 GCC COUNTRIES: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 256 IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 257 NORTH AMERICA: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 258 EUROPE: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 259 ASIA PACIFIC: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 260 LATIN AMERICA: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 261 GCC COUNTRIES: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 262 IVD REAGENTS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 263 NORTH AMERICA: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 264 EUROPE: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 265 ASIA PACIFIC: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 266 LATIN AMERICA: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 267 GCC COUNTRIES: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 268 IVD REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 269 KEY IVD REAGENTS PROVIDED BY MAJOR PLAYERS IN NORTH AMERICA
  • TABLE 270 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 271 NORTH AMERICA: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 272 NORTH AMERICA: IVD TESTS CONDUCTED, BY COUNTRY, 2022-2029 (BILLION UNIT)
  • TABLE 273 NORTH AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 274 NORTH AMERICA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 275 NORTH AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 276 NORTH AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 277 NORTH AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 278 NORTH AMERICA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 279 NORTH AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 280 US: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 281 US: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 282 US: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 283 US: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 284 US: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 285 US: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 286 US: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 287 CANADA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 288 CANADA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 289 CANADA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 290 CANADA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 291 CANADA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 292 CANADA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 293 CANADA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 294 KEY IVD REAGENTS PROVIDED BY MAJOR PLAYERS IN EUROPE
  • TABLE 295 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 296 EUROPE: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 297 EUROPE: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 298 EUROPE: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 299 EUROPE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 300 EUROPE: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 301 EUROPE: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 302 EUROPE: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 303 EUROPE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 304 GERMANY: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 305 GERMANY: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 306 GERMANY: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 307 GERMANY: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 308 GERMANY: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 309 GERMANY: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 310 GERMANY: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 311 UK: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 312 UK: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 313 UK: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 314 UK: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 315 UK: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 316 UK: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 317 UK: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 318 FRANCE: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 319 FRANCE: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 320 FRANCE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 321 FRANCE: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 322 FRANCE: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 323 FRANCE: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 324 FRANCE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 325 ITALY: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 326 ITALY: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 327 ITALY: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 328 ITALY: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 329 ITALY: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 330 ITALY: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 331 ITALY: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 332 SPAIN: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 333 SPAIN: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 334 SPAIN: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 335 SPAIN: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 336 SPAIN: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 337 SPAIN: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 338 SPAIN: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 339 REST OF EUROPE: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 340 REST OF EUROPE: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 341 REST OF EUROPE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 342 REST OF EUROPE: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 343 REST OF EUROPE: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 344 REST OF EUROPE: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 345 REST OF EUROPE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 346 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 347 ASIA PACIFIC: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 348 ASIA PACIFIC: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 349 ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 350 ASIA PACIFIC: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 351 ASIA PACIFIC: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 352 ASIA PACIFIC: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 353 ASIA PACIFIC: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 354 ASIA PACIFIC: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 355 JAPAN: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 356 JAPAN: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 357 JAPAN: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 358 JAPAN: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 359 JAPAN: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 360 JAPAN: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 361 JAPAN: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 362 CHINA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 363 CHINA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 364 CHINA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 365 CHINA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 366 CHINA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 367 CHINA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 368 CHINA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 369 INDIA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 370 INDIA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 371 INDIA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 372 INDIA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 373 INDIA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 374 INDIA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 375 INDIA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 376 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 377 REST OF ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 378 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 379 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 380 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 381 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 382 REST OF ASIA PACIFIC: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 383 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 384 LATIN AMERICA: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 385 LATIN AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 386 LATIN AMERICA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 387 LATIN AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 388 LATIN AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 389 LATIN AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 390 LATIN AMERICA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 391 LATIN AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 392 BRAZIL: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 393 BRAZIL: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 394 BRAZIL: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 395 BRAZIL: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 396 BRAZIL: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 397 BRAZIL: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 398 BRAZIL: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 399 MEXICO: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 400 MEXICO: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 401 MEXICO: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 402 MEXICO: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 403 MEXICO: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 404 MEXICO: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 405 MEXICO: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 406 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 407 REST OF LATIN AMERICA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 408 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 409 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 410 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 411 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 412 REST OF LATIN AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 413 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 414 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 415 MIDDLE EAST & AFRICA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 416 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 417 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 418 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 419 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 420 MIDDLE EAST & AFRICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 421 GCC COUNTRIES: MACROECONOMIC INDICATORS
  • TABLE 422 GCC COUNTRIES: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 423 GCC COUNTRIES: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 424 GCC COUNTRIES: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 425 GCC COUNTRIES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 426 GCC COUNTRIES: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 427 GCC COUNTRIES: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 428 GCC COUNTRIES: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 429 GCC COUNTRIES: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 430 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 431 KINGDOM OF SAUDI ARABIA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 432 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 433 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 434 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 435 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 436 KINGDOM OF SAUDI ARABIA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 437 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 438 UNITED ARAB EMIRATES: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 439 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 440 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 441 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 442 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 443 UNITED ARAB EMIRATES: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 444 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 445 OTHER GCC COUNTRIES: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 446 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 447 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 448 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 449 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 450 OTHER GCC COUNTRIES: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 451 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IVD REAGENTS MARKET, 2021-2023
  • TABLE 452 IVD REAGENTS MARKET: DEGREE OF COMPETITION
  • TABLE 453 IVD REAGENTS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 454 IVD REAGENTS MARKET: APPLICATION FOOTPRINT
  • TABLE 455 IVD REAGENTS MARKET: TEST TYPE FOOTPRINT
  • TABLE 456 IVD REAGENTS MARKET: REGION FOOTPRINT
  • TABLE 457 IVD REAGENTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 458 IVD REAGENTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 459 IVD REAGENTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 460 IVD REAGENTS MARKET: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 461 IVD REAGENTS MARKET: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 462 IVD REAGENTS MARKET: OTHER DEVELOPMENTS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 463 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 464 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 465 DANAHER CORPORATION: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 466 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 467 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 468 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 469 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 470 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 471 ABBOTT: COMPANY OVERVIEW
  • TABLE 472 ABBOTT: PRODUCTS OFFERED
  • TABLE 473 ABBOTT: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 474 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 475 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 476 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 477 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 478 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 479 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 480 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 481 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 482 ILLUMINA, INC.: PRODUCTS OFFERED
  • TABLE 483 ILLUMINA, INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 484 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 485 BIOMERIEUX: PRODUCTS OFFERED
  • TABLE 486 BIOMERIEUX: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 487 BD: COMPANY OVERVIEW
  • TABLE 488 BD: PRODUCTS OFFERED
  • TABLE 489 BD: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 490 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 491 HOLOGIC, INC.: PRODUCTS OFFERED
  • TABLE 492 HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 493 HOLOGIC, INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 494 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 495 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
  • TABLE 496 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 497 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 498 SYSMEX CORPORATION: PRODUCTS OFFERED
  • TABLE 499 SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 500 SYSMEX CORPORATION: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 501 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 502 QIAGEN N.V.: COMPANY OVERVIEW
  • TABLE 503 QIAGEN N.V.: PRODUCTS OFFERED
  • TABLE 504 QIAGEN N.V.: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 505 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 506 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • TABLE 507 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 508 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 509 REVVITY: COMPANY OVERVIEW
  • TABLE 510 REVVITY: PRODUCTS OFFERED
  • TABLE 511 REVVITY: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 512 REVVITY: OTHER DEVELOPMENTS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 513 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 514 DIASORIN S.P.A.: PRODUCTS OFFERED
  • TABLE 515 DIASORIN S.P.A.: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 516 GRIFOLS S.A.: COMPANY OVERVIEW
  • TABLE 517 GRIFOLS S.A.: PRODUCTS OFFERED
  • TABLE 518 GRIFOLS S.A.: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 519 WERFEN, S.A.: COMPANY OVERVIEW
  • TABLE 520 WERFEN, S.A.: PRODUCTS OFFERED
  • TABLE 521 WERFEN, S.A.: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 522 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 523 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • TABLE 524 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 525 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 526 CHEMBIO DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • TABLE 527 CHEMBIO DIAGNOSTICS, INC.: PRODUCTS OFFERED
  • TABLE 528 SURMODICS, INC.: COMPANY OVERVIEW
  • TABLE 529 SURMODICS, INC.: PRODUCTS OFFERED
  • TABLE 530 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 531 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 532 MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.: COMPANY OVERVIEW
  • TABLE 533 CANVAX: COMPANY OVERVIEW
  • TABLE 534 PRESTIGE DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 535 ADALTIS S.R.L.: COMPANY OVERVIEW
  • TABLE 536 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 IVD REAGENTS MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 IVD REAGENTS MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 6 IVD REAGENTS MARKET: TOP-DOWN APPROACH
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • FIGURE 8 IVD REAGENTS MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • FIGURE 9 IVD REAGENTS MARKET, BY TECHNOLOGY, 2024-2029 (USD MILLION)
  • FIGURE 10 IVD REAGENTS MARKET, BY APPLICATION, 2024-2029 (USD MILLION)
  • FIGURE 11 IVD REAGENTS MARKET, BY TEST TYPE, 2024-2029 (USD MILLION)
  • FIGURE 12 IVD REAGENTS MARKET, BY END USER, 2024-2029 (USD MILLION)
  • FIGURE 13 IVD REAGENTS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • FIGURE 14 INCREASING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
  • FIGURE 15 CHINA TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 16 US AND LABORATORY TESTS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN IVD REAGENTS MARKET IN 2023
  • FIGURE 17 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 18 IVD REAGENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 19 CRITICAL IMPACT AREAS OF IVD REAGENTS
  • FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 21 IVD REAGENTS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 22 IVD REAGENTS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 23 IVD REAGENTS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 24 IVD REAGENTS MARKET: INVESTMENT AND FUNDING SCENARIO, 2019-2024
  • FIGURE 25 IVD REAGENTS MARKET: PATENT ANALYSIS, JANUARY 2014-MARCH 2024
  • FIGURE 26 IVD REAGENTS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD REAGENTS, BY END USER
  • FIGURE 28 KEY BUYING CRITERIA FOR IVD REAGENTS, BY END USER
  • FIGURE 29 NORTH AMERICA: IVD REAGENTS MARKET SNAPSHOT
  • FIGURE 30 ASIA PACIFIC: IVD REAGENTS MARKET SNAPSHOT
  • FIGURE 31 IVD REAGENTS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD MILLION)
  • FIGURE 32 IVD REAGENTS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
  • FIGURE 33 FINANCIAL METRICS
  • FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, (2021-2023)
  • FIGURE 35 IVD REAGENTS MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 36 IVD REAGENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 37 IVD REAGENTS MARKET: COMPANY FOOTPRINT
  • FIGURE 38 IVD REAGENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 44 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 45 BIOMERIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 46 BD: COMPANY SNAPSHOT (2023)
  • FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 48 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 50 QIAGEN N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 51 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 52 REVVITY: COMPANY SNAPSHOT (2023)
  • FIGURE 53 DIASORIN S.P.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 54 GRIFOLS S.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 55 WERFEN, S.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 56 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 57 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 58 SURMODICS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 59 MERCK KGAA: COMPANY SNAPSHOT (2023)